EGFR and non-small cell lung carcinoma: Given that primary NSCLC with a TKI-sensitizing EGFR-mutant may not harbor resistant clones at the start of TKI treatment, we anticipate that combination therapy with afatinib and osimertinib may improve patient prognosis by reducing the likelihood of the resistant clone appearing, which is supported by previous research [45, 46].